|1.||Chorea (Rheumatic Chorea)
|2.||Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
|3.||Facial Paralysis (Facial Palsy)
|4.||Schizophrenia (Dementia Praecox)
|5.||Movement Disorders (Movement Disorder)
|1.||Jankovic, Joseph: 8 articles (02/2013 - 11/2002)|
|2.||Yakimovskii, A F: 7 articles (04/2011 - 08/2002)|
|3.||Tarazi, Frank I: 6 articles (09/2005 - 02/2002)|
|4.||Zhang, Kehong: 6 articles (09/2005 - 02/2002)|
|5.||Baldessarini, Ross J: 6 articles (09/2005 - 02/2002)|
|6.||Iakimovskiĭ, A F: 5 articles (02/2013 - 10/2002)|
|7.||Bishnoi, Mahendra: 5 articles (02/2009 - 02/2007)|
|8.||Kulkarni, Shrinivas K: 5 articles (02/2009 - 02/2007)|
|9.||Chopra, Kanwaljit: 5 articles (02/2009 - 02/2007)|
|10.||Masuo, Yoshinori: 5 articles (06/2007 - 12/2002)|
|1.||Tetrabenazine (Nitoman)FDA Link
01/01/2008 - "In clinical studies, tetrabenazine has been found to be effective in a wide range of hyperkinetic movement disorders, including small numbers (<50) of patients with TS in some studies. "
01/01/1982 - "In a double-blind crossover trial of tetrabenazine versus placebo, 19 patients with a variety of hyperkinetic movement disorders were evaluated. "
04/01/2014 - "We assessed and characterized these hyperkinetic movements in detail and investigated the effect of tetrabenazine (TBZ) treatment. "
11/01/2013 - "VMAT2 is also a target of tetrabenazine, a drug used in the treatment of hyperkinetic movement disorders, including TD. "
07/01/2012 - "Tetrabenazine (TBZ) is a monoamine storage inhibitor that was first introduced in the 1970s for the management of hyperkinetic movement disorders. "
|2.||Botulinum Toxins (Botulinum Toxin)IBA
02/01/2012 - "These two symptoms showed improvement after botulinum toxin treatment, but only hyperkinesis showed a positive correlation when objective and subjective evaluations were performed. "
03/01/2007 - "When focal hyperkinetic movements dominate the picture, botulinum toxin injection is a useful adjunct to medications."
02/01/1997 - "Botulinum toxin is now widely used in the treatment of several hyperkinetic movement disorders. "
09/15/2007 - "Injection of botulinum toxin was effective in reducing muscular hyperkinesis in the hemiface opposite that affected by facial paralysis, with mild and short-term side effects."
09/15/2007 - "Botulinum toxin in facial palsy: an effective treatment for contralateral hyperkinesis."
|3.||Dopamine (Intropin)FDA LinkGeneric
09/01/2004 - "Our data support the view that the psychostimulant ameliorates performance in Fmr1 knockout mice by improving merely cognitive functions through its action on prefrontal cortical dopamine, irrespective of its action on motor hyperactivity. "
12/09/1985 - "In this study it was found that after daily intra-VTA injection with NT, both the motor hyperactivity and increase in dopamine metabolism were significantly enhanced. "
08/18/2010 - "DAT-CI mutants display enhanced striatal extracellular dopamine levels and basal motor hyperactivity. "
10/19/2006 - "During hyperkinesia, corticostriatal activity became largely asynchronous, while during dopamine-depletion the synchronicity increased. "
10/19/2006 - "Surprisingly, although most cortical and striatal neurons ( approximately 70%) changed firing rate during the transition between dopamine-related hyperkinesia and akinesia, the overall cortical firing rate remained unchanged. "
|4.||Haloperidol (Haldol)FDA LinkGeneric
05/01/1997 - "Results indicated that haloperidol was effective in ameliorating the hyperkinesia in rats with bilateral globus pallidus lesions but not in rats with ventral pallidum/substantia innominata lesions. "
08/16/1977 - "When tested as long as 508 days after the last administration, however, Cebus monkeys responded to haloperidol with several episodes of hyperkinesis, even at challenge doses considerably lower than those in the original treatment."
05/01/1962 - "[On the subject of therapy of hyperkinesia with haloperidol]."
05/30/2007 - "These findings suggest that the current therapeutic management of METH-induced psychoses with haloperidol may be contraindicated because of a resultant GABAergic cell death in the SNr, which may predispose some individuals to the development of hyperkinetic movement disorders and seizures."
01/01/1993 - "Haloperidol induced catalepsy, tremor, dystony, hyperkinesia, and stereotypy. "
|5.||Antipsychotic Agents (Antipsychotics)IBA
12/01/2009 - "It has been found to be beneficial in hyperkinetic movement disorders without carrying the extrapyramidal side effects that are characteristic of neuroleptics. "
11/01/1967 - "[Causes of persisting extrapyramidal hyperkinesis after prolonged administration of major tranquilizers]."
04/01/1967 - "[Apropos of the forms of frequency and reversibility of choreiform hyperkinesia as a late complication of prolonged therapy with neuroleptics]."
04/01/1967 - "[On the problem of persistent extrapyramidal hyperkinesia following prolonged use of neuroleptics]."
06/01/1966 - "[Paroxysmal hyperkinesis provoked by neuroleptics]."
|6.||Methylphenidate (Ritalin)FDA LinkGeneric
07/01/2001 - "The efficacy and adverse reactions produced by methylphenidate (MPD) therapy were evaluated in 141 patients with hyperkinetic disorder or pervasive developmental disorder (PDD) with hyperkinesia. "
07/01/2001 - "[Methylphenidate therapy in 141 patients with hyperkinetic disorder or with pervasive developmental disorder and hyperkinesia]."
12/01/1986 - "The 7 boys and 4 girls were enrolled in a Special Day classroom for hyperkinesis and behavior problems and were being given methylphenidate (Ritalin). "
08/05/1985 - "Effects of methylphenidate on whirler mice: an animal model for hyperkinesis."
12/01/1980 - "The assay has been used to investigate the pharmacokinetics of methylphenidate administered to 6 children for treatment of hyperkinesis. "
|7.||Valproic Acid (Valproate, Semisodium)FDA LinkGeneric
10/01/2006 - "Five of the 11 MRS items improved significantly more in patients receiving divalproex ER than placebo: less need for sleep (p <or= .01), more energetic (p <or= .05), increased activity (p <or= .05), generalized motor hyperactivity (p <or= .05), and racing thoughts (p <or= .001). "
01/01/2006 - "In the rare subgroup of HD patients suffering from myoclonic hyperkinesia, valproic acid is a possible alternative treatment."
06/01/2001 - "He was started on sodium valproate and continued with the drug (30 mg/kg/day) on which, he showed improvement in speech, behavior, hyperkinesis and frequency of convulsions during the follow-up."
01/01/2006 - "Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series."
03/01/1983 - "Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. "
|8.||Levodopa (L Dopa)FDA LinkGeneric
02/01/2015 - "In a second experiment, we applied different forms of repetitive transcranial magnetic stimulation over the right inferior frontal cortex in a new group of dyskinetic patients who were taking a supramaximal dose of levodopa, to verify the clinical relevance of this area in controlling the development of hyperkinetic movements. "
12/15/2010 - "Chronic treatment with levodopa-induced forelimb hyperkinesia and shortened the duration of rotational behavior. "
01/01/2007 - "Hyperactivity lasted for approximately 2 hours after each levodopa injection and then returned to baseline, but the amount of hyperkinesia increased with additional days of levodopa treatment, even though the daily levodopa dose was not changed. "
02/01/1999 - "There was a marked reduction in L-dopa-induced climbing, stereotypy and hyperkinesis and behaviour more closely resembled that of normal unlesioned marmosets. "
02/01/1999 - "A degree of behavioral tolerance was encountered, but antiparkinsonian activity was preserved and elicited behaviour was free of hyperkinesis and stereotypy and more naturalistic than that seen with L-dopa. "
|9.||Dopamine Receptors (Dopamine Receptor)IBA
01/01/2000 - "The involvement of altered dopamine receptor sensitivity in several extrapyramidal dys- and hyperkinesia has been hypothesized. "
09/01/1998 - "In line with current models of basal ganglia functions, these findings indicate that inactivation of the globus pallidus reduced spontaneous motor activity and motor hyperactivity after dopamine receptor stimulation. "
01/01/2015 - "Tardive dyskinesia (TD) is a serious, disabling and potentially permanent, neurological hyperkinetic movement disorder that occurs after months or years of taking dopamine receptor-blocking agents. "
02/01/2008 - "Tardive dyskinesia (TD) is a hyperkinetic movement disorder induced by dopamine receptor blocking drugs (DRBDs). "
05/01/1993 - "We reviewed the medical records and videotapes of 100 patients with tardive dyskinesia (TD) referred to our movement disorders clinic to characterize the spectrum of hyperkinetic movement disorders caused by dopamine receptor blocking drugs (DRBD). "
|10.||Pimozide (Orap)FDA Link
01/01/1984 - "Hypothalamo-pituitary functions were examined in thirteen children with behavioral disorders (six with hyperkinesia, four with autism, two with tic and one with schizophrenia) before and during treatment with pimozide, an antidopaminergic drug. "
08/01/1984 - "Pimozide and haloperidol improved hyperkinesia; none of the drugs significantly affected motor performance. "
05/01/1972 - "Blockade by pimozide of (+)-amphetamine-induced hyperkinesia in mice."
08/01/1984 - "Eighteen patients with Huntington's chorea were examined before and after neuroleptic treatment (haloperidol, pimozide, tiapride) to study the effect of such treatment on hyperkinesia and motor performance. "
04/01/1990 - "It was demonstrated that cocaine-induced motor hyperactivity could be blocked by pimozide, a dopamine receptor blocker, suggesting that dopamine was involved in cocaine-induced hyperactivity. "
12/01/2003 - "Although a single solid graft of embryonic DA neurons can prevent progression of some lesioned-induced behavioral abnormalities such as LD-induced rotation and dystonia, it significantly increases hyperkinetic movements of the contralateral forelimb. "
12/01/2003 - "Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats."
12/01/1996 - "These results suggest that implantation of a GABA-releasing source may be an effective alternative to intrathalamic fetal-tissue grafts or lesions as an experimental approach to the treatment of hyperkinetic movement disorders."
03/01/2006 - "The results show that grafts placed in the caudal, but not the rostral, part are effective in reducing the L-DOPA-induced limb and orolingual dyskinesia, predominantly seen as hyperkinesia. "
03/01/1975 - "An investigation of constituents in the complex (overall) resistance of deep-lying brain structures of patients with hyperkinesis treated by employing implanted electrodes helped disclose some specific features common to the impedance of conduction pathways, ventricles and some basal ganglia. "
01/01/1963 - "[Utilization of multiple electrodes implanted in the subcortical structure of the human brain for the treatment of hyperkinesis]."
12/01/2013 - "Local field potentials (LFPs) recorded from deep brain stimulation electrodes implanted in the globus pallidus internus (GPi) of patients with hyperkinetic movement disorders (dystonia and Tourette's syndrome) have shown desynchronized activity at 8-20 Hz and synchronized activity at 30-90 Hz during voluntary movements. "
|3.||Drug Therapy (Chemotherapy)
06/01/1976 - "Although drug therapy is helpful in the control of many children with hyperkinesia, alternative and adjunctive therapies are needed also, for a number of reasons: 1) not all of these children improve with medication; 2) the drugs may have adverse physiologic effects which at the least dictate caution in their use; 3) medication alone does not always return responding children to normal functioning; and 4) drug action cannot often be used to help with problems occurring in the children's home setting after school hours. "
10/01/2006 - "Early-onset generalized dystonia attributable to a DYT1 gene mutation is a hyperkinetic movement disorder that responds poorly to pharmacotherapy. "
11/01/1990 - "Tardive dyskinesia is a potentially irreversible syndrome of involuntary hyperkinetic movements that occur in predisposed persons receiving extended neuroleptic (antipsychotic) drug therapy. "
01/01/1978 - "[Effectiveness of treating facial hyperkinesis with acupuncture reflex therapy and blockades]."
01/01/2002 - "In view of pathogenetic features of this pathological process we have chosen reflexotherapy to be instituted in our patients: auriculopuncture, electro-corporal- and acupuncture which have been shown to be expedient and effective in treating 65 patients with local hyperkinesis (blepharospasm, facial paraspasm, writer's spasm, spasmodic torticollis). "